Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4874979 | 0.91 | CYP2D6 (0.30) | HRH1CYP2D6 | |
| SCHEMBL4870574 | 0.91 | MTOR (0.31) | ALDH1A1 | |
| SCHEMBL4877282 | 0.89 | — | — | |
| SCHEMBL4876105 | 0.89 | KCNH2 (0.35) | — | |
| SCHEMBL4867762 | 0.89 | MCHR1 (0.31) | KDM4EMCHR1 | |
| SCHEMBL4877135 | 0.89 | BRD4 (0.31) | MCHR1 | |
| SCHEMBL4877179 | 0.88 | GAK (0.35) | ALDH1A1 | |
| SCHEMBL4874640 | 0.88 | KCNH2 (0.32) | — | |
| SCHEMBL4878870 | 0.83 | PDE5A (0.42) | PDE5AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4868392 | 0.83 | CBX7 (0.40) | HRH1CYP2D6KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | HRH1 3900/4885CYP2D6 1327/4885PDE5A 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.